Skip to main content

  | मौसम…

411 समाचार
Public archive edition · Attributed source reporting with original dates · AI drafts are excluded

New drug from lizard's saliva

Licensed archive · Attributed source reporting

Wikinews contributors☆ सेव करें

411 Brief

A chemical part of the saliva of a poisonous lizard, the Gila monster, has become an integral partner in the control of Type 2 diabetes. The U.S. Food and Drug Administration has approved its use for people who have not achieved adequate control of their diabetes with oral medications. Byetta, or exenatide, is produced by Amylin Pharmaceuticals. It is injected before eating morning and evening meals as part of a combination treatment with oral drugs. The FDA said it could be approved as a stand-alone treatment if the drug companies can support

A chemical part of the saliva of a poisonous lizard, the Gila monster, has become an integral partner in the control of Type 2 diabetes. The U.S. Food and Drug Administration has approved its use for people who have not achieved adequate control of their diabetes with oral medications.

Byetta, or exenatide, is produced by Amylin Pharmaceuticals. It is injected before eating morning and evening meals as part of a combination treatment with oral drugs. The FDA said it could be approved as a stand-alone treatment if the drug companies can support such use with data.

Eli Lilly & Co. was the development partner in creation of the drug.

"With Byetta's demonstrated effects on blood sugar and its safety profile, physicians and patients now have a new approach to fight the growing diabetes epidemic," said Sidney Taurel, CEO of Lilly.

Sources & reporting note

Licensed archive reporting by Wikinews contributors. Text: Public domain (https://en.wikinews.org/wiki/Wikinews:Copyright). Original source date retained. 411 has not independently verified this archive report.

Read the source: Wikinews ↗

Source published 30 Apr 2005, 05:30 am IST

इस खबर को पढ़ें:
Report an error

Reports and optional email addresses are visible only to the newsroom. Please avoid private or sensitive information.

आपके लिए और